The American Journal of Medicine
Volume 122, Issue 6 , Pages 582.e1-582.e9, June 2009

C-Reactive Protein Elicits White Blood Cell Activation in Humans

  • Radjesh J. Bisoendial, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationRequests for reprints should be addressed to Radjesh J. Bisoendial, MD, PhD, Department of Clinical Immunology and Rheumatology, Academic Medical Center, Meibergdreef 9, Room F4-222, 1105 AZ Amsterdam, The Netherlands
  • ,
  • Rakesh S. Birjmohun, MD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  • ,
  • Fatima Akdim, MD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  • ,
  • Cornelis van ‘t Veer, PhD

      Affiliations

    • Department of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
  • ,
  • C. Arnold Spek, PhD

      Affiliations

    • Department of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
  • ,
  • Daniel Hartman, MD, PhD

      Affiliations

    • deCODE genetics, Reykjavik, Iceland
  • ,
  • Els R. de Groot

      Affiliations

    • Department of Immunopathology, Sanguin Research, Amsterdam, The Netherlands
  • ,
  • Danute M. Bankaitis-Davis, PhD

      Affiliations

    • Source Molecular Diagnostics, Boulder, Colorado
  • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  • ,
  • Erik S.G. Stroes, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

Abstract 

Objective

Consistent epidemiologic evidence suggests that acute infections increase the risk for acute cardiovascular events. We tested in humans whether activation of peripheral leukocytes in reaction to the administration of recombinant human C-reactive protein (rhCRP) may provide a mechanism for infectious diseases to promote atherosclerotic disease.

Methods and Results

By using quantitative real-time polymerase chain reaction analysis, whole-blood expression profiles were analyzed for 95 inflammatory markers before and after infusion of 1.25 mg/kg rhCRP in 5 male volunteers. Relevant transcript levels were measured at baseline and 4 and 8 hours after rhCRP-infusion. CRP caused significant up-regulation of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-1, plasminogen activator urokinase, macrophage inflammatory protein 1α, and nuclear factor of kappa B inhibitor mRNAs in peripheral leukocytes. mRNA up-regulation of MMP-9 and MCP-1 was 17- and 11-fold, respectively. The corresponding increase in plasma protein levels of MMP-9 (78±32 ng/mL to 109±41 ng/mL; P=.014) and MCP-1 (312±92 pg/mL to 2590±898 pg/mL; P=.007) closely mirrored mRNA findings. Also, in whole-blood culture stimulation assays, CRP induced proinflammatory changes. Notably, heat inactivation abolished the capacity of CRP to evoke these proinflammatory changes, excluding a role for contaminants within the purified CRP preparation.

Conclusion

CRP elicits activation of peripheral leukocytes with ensuing secretion of plaque-destabilizing mediators. These findings are consistent with the hypothesis that infectious diseases trigger manifestations of atherosclerosis, in which CRP elevation might contribute to the onset of cardiovascular events.

Keywords: Atherosclerosis, Cardiovascular everts, C-reactive protein, Infection, Leukocytes

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: This work was in part supported by a grant from Pfizer, which had no involvement in the data analysis/interpretation or writing the manuscript. John J. P. Kastelein is an established investigator of The Netherlands Heart Foundation (2000D039).

 Conflict of Interest: None.

 Authorship: All authors had access to the data and played a role in writing.

PII: S0002-9343(09)00116-8

doi:10.1016/j.amjmed.2008.11.032

The American Journal of Medicine
Volume 122, Issue 6 , Pages 582.e1-582.e9, June 2009